{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:42Z","timestamp":1786984302909,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.amjopharm.2006.03.003","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T17:11:45Z","timestamp":1149181905000},"page":"25-35","source":"Crossref","is-referenced-by-count":10,"title":["Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities"],"prefix":"10.1016","volume":"4","author":[{"given":"Juliette","family":"Taylor Tour\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rhona Limcangco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky A","family":"Briesacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.amjopharm.2006.03.003_bib1","first-page":"105","article-title":"Motor and mental aspects of extrapyramidal syndromes","volume":"10","author":"Casey","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archinte.1994.00420100093012","article-title":"Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication","volume":"154","author":"Avorn","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib3","series-title":"Geriatric Medicine","first-page":"55","article-title":"Principles of pharmacology","author":"Avorn","year":"1996"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00002512-199303040-00004","article-title":"The problems of anticholinergic adverse effects in older patients","volume":"3","author":"Feinberg","year":"1993","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","article-title":"Neuroleptic-induced Parkinson's syndrome: Clinical features and results of treatment with levodopa","volume":"51","author":"Hardie","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2006.03.003_bib8","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1177\/089198879500800104","article-title":"Neuroleptic treatment of agitation and psychosis in dementia","volume":"8","author":"Devanand","year":"1995","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1532-5415.1987.tb02315.x","article-title":"Neuroleptics and the elderly","volume":"35","author":"Peabody","year":"1987","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.1994.03510290040034","article-title":"Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations","volume":"271","author":"Shorr","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1532-5415.1998.tb02540.x","article-title":"Newer psychotropic medication use in nursing home residents","volume":"46","author":"Lasser","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib12","series-title":"Code of Federal Regulations. 42 CFR 483.60","year":"2005"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib13","series-title":"Medicare Current Beneficiary Survey (MCBS)","author":"Centers for Medicare & Medicaid Services","year":"2005"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1532-5415.2005.53161.x","article-title":"National estimates of medication use in nursing homes: Findings from the 1997 Medicare current beneficiary survey and the 1996 Medical Expenditure Survey","volume":"53","author":"Doshi","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.165.11.1280","article-title":"The quality of antipsychotic drug prescribing in nursing homes","volume":"165","author":"Briesacher","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib16","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.1997.00440350031003","article-title":"Explicit criteria for determining potentially inappropriate medication use by the elderly. An update","volume":"157","author":"Beers","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"De Dyn","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib21","first-page":"149","article-title":"Serum anticholinergic activity levels and delirium in the elderly","volume":"5","author":"Tune","year":"2000","journal-title":"Semin Clin Neuropsychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1176\/ajp.149.10.1393","article-title":"Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium","volume":"149","author":"Tune","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1532-5415.2002.50208.x","article-title":"Use of anticholinergic medications by older adults with dementia","volume":"50","author":"Roe","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/bmj.315.7115.1096","article-title":"Optimising drug treatment for elderly people: The prescribing cascade","volume":"315","author":"Rochon","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00002512-200219040-00002","article-title":"Pharmacological treatment of psychosis and agitation in elderly patients with dementia: Four decades of experience","volume":"19","author":"Kindermann","year":"2002","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0002-9343(99)80104-1","article-title":"Neuroleptic drug exposure and treatment of parkinsonism in the elderly: A case-control study","volume":"99","author":"Avorn","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/apt.8.1.49","article-title":"Use of atypical antipsychotic drugs in old age psychiatry","volume":"8","author":"Bouman","year":"2002","journal-title":"Adman Psycbiatr Treat"},{"issue":"Suppl 10","key":"10.1016\/j.amjopharm.2006.03.003_bib28","first-page":"5","article-title":"Receptor pharmacology of neuroleptics: Relation to clinical effects","volume":"60","author":"Richelson","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.amjopharm.2006.03.003_bib29","first-page":"CD000440","article-title":"Risperidone versus typical antipsychotic mediation for schizophrenia","author":"Kennedy","year":"2000","journal-title":"Cochrane Database Syst Rep"},{"issue":"2","key":"10.1016\/j.amjopharm.2006.03.003_bib30","first-page":"CD001359","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib31","first-page":"12","article-title":"Clozapine use in female geriatric patients with psychoses","volume":"8","author":"Chengappa","year":"1995","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1099-1166(199705)12:5<553::AID-GPS547>3.0.CO;2-U","article-title":"Outcome of clozapine therapy for elderly patients with refractory primary psychosis","volume":"12","author":"Sajatovic","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1345\/aph.1A068","article-title":"Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine","volume":"35","author":"Schillevoort","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine: A novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib35","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1345\/aph.19259","article-title":"Clozapine-induced hypersalivation","volume":"34","author":"Davydov","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00004850-199707000-00005","article-title":"Trihexyphenidyl treatment of clozapine-induced hypersalivation","volume":"12","author":"Spivak","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib37","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1176\/appi.ajp.158.8.1329-a","article-title":"Biperiden for excessive sweating from clozapine","volume":"158","author":"Richardson","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib38","volume":"Vol 121","year":"2004"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib39","first-page":"387","article-title":"A study of pharmacy services in North Carolina rest homes","volume":"11","author":"Eckel","year":"1971","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib40","doi-asserted-by":"crossref","first-page":"M131","DOI":"10.1093\/gerona\/51A.3.M131","article-title":"Regulatory environment and psychotropic use in board-and-care facilities: Results of a 10-state study","volume":"51","author":"Spore","year":"1996","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00000446-200308000-00014","article-title":"Policy perspectives: Assisted living and the role of nursing","volume":"103","author":"Mitty","year":"2003","journal-title":"Am J Nurs"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib42","series-title":"Trends in antipsychotic use in long-term care facilities: Report submitted to Centers for Medicare & Medicaid Services","author":"Briesacher","year":"2004"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1176\/appi.ps.51.3.354","article-title":"Use of nursing homes in the care of persons with severe mental illness: 1985\u20131995","volume":"51","author":"Mechanic","year":"2000","journal-title":"Psycbiatr Serv"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib44","first-page":"59","article-title":"Assisted living and use of mental health services among Medicaid beneficiaries with schizophrenia","volume":"6","author":"Gilmer","year":"2003","journal-title":"J Ment Health Policy Econ"},{"key":"10.1016\/j.amjopharm.2006.03.003_bib45","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1176\/appi.ps.54.12.1644","article-title":"An administrator's perspective on mental health in assisted living","volume":"54","author":"Wagenaar","year":"2003","journal-title":"Psychiatr. Serv"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594606000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594606000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T01:23:33Z","timestamp":1547601813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594606000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1543594606000043"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2006.03.003","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}